Clearmind Medicine Inc. (Nasdaq, CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established with the university’s technology transfer company, Yissum.
The first project, led by Professor Dmitry Tsvelikhovsky, Professor Masha Niv and Professor Avi Priel, was designed to investigate and discover innovative synthetic molecules based on known psychedelic chemical motifs. The project included rational design of novel candidates, in-silico 3D docking studies on the 5HT2A serotonin receptor, and screening of the candidates in an in-vitro platform, to assess the receptor activation.
The second project, led by Professor Ahmad Masarwa, Professor Avi Priel, and Professor Rami Yaka, was aimed to synthesize and evaluate the potential therapeutic effect of various chemical psychedelic analogues. The work included alterations of different regions of known molecules, to potentially improve their binding capabilities to the 5HT2A receptor. The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.
Clearmind’s CEO, Dr. Adi Zuloff-Shani
“We are excited about the results of these projects. These results are proof of the fruitful collaboration between Clearmind and leading academic institutions, which we value and appreciate. These projects align with Clearmind’s overarching mission to continue developing and expanding our intellectual property portfolio for next-generation novel psychedelic drug candidates, serving patients with unmet needs through a state-of-the-art drug discovery approach in medicinal chemistry and pharmacology”.
These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 11,000 patents globally; licensed over 1,140 technologies and has spun out more than 200 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, ICL, Intel, Johnson & Johnson, Merck, Novartis and many more.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.